Skip to main content

Table 3 Overall survival according to PDGFRα and PDGFRβ mutational status

From: PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome

Mutational status Patients N (%) Overall survival
   Median (months) % at 5y HR P
PDGFR-A13      
  · WT (AA) 60 (82%) 37.1 14% 0.96 0.934
  · SNP (AG) 13 (18%) 21.7 41%   
PDGFR-B19      
  · WT (AA) 33 (42%) NR 51% 1.93 0.073
  · SNP (AG,GG) 45 (58%) 37.1 17%   
  1. WT: wild type; SNP: single nucleotide polymorphism; N: number; 5y: 5 years; HR: hazard ratio; NR: not reached.
\